FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989346945> ?p ?o ?g. }

• W2989346945 endingPage "4548" @default.
• W2989346945 startingPage "4548" @default.
• W2989346945 abstract "Cyclosporine A (CsA) alone or in combination with mycophenolate mofetil (MMF) has been used as graft-versus-host-disease (GvHD) prophylaxis since the early development of reduced intensity conditioning (RIC). The association of CsA+MMF, while commonly used after transplantation from a matched unrelated donor (MUD), has never been tested in a large randomized prospective trial. We retrospectively investigated the outcomes of adult patients with AML in complete remission (CR) undergoing a MUD transplant using CsA+MMF or CsA alone as GvHD prophylaxis, transplanted between 2007-2017 and registered with the ALWP of the EBMT. Of the 497 patients who were evaluated, 183 received CsA alone and 314 received CsA+MMF. The median age at transplant was similar, being 59 (range, 20-75) years in the CsA group and 60 (range, 21-75) years in the CsA+MMF group. All patients underwent a RIC regimen with fludarabine and busulfan and received anti-thymocyte globulin as part of the conditioning. The median follow-up was 33 (range, 18-60) months in the CsA group and 34 (range, 18-75) months in the CsA+MMF group. Disease status at transplant was first complete remission (CR1) for 81% (n=149) in CsA group and 86% (n=268) in CsA+MMF group (p=NS). Poor risk cytogenetics was reported for 19% of patients who received GvHD prophylaxis with CsA alone and for 15% of patients receiving CsA+MMF (p=NS). Peripheral blood stem cells (PBSC) was the graft source in 93% of patients receiving CsA alone and in 96% of patients who received CsA+MMF (p=0.17). Female to male mismatch was present in 13% and 15% of patients in the CsA goup and CsA+MMF group respectively, (p=NS). All but 2 patients engrafted. The 100 day cumulative incidence (CI) of grade II-IV and grade III-IV GvHD were 30% and 10%, respectively. The 2-year CI chronic GvHD was 35% and CI of extensive cGvHD was 15%. The 2-year CI of non-relapse mortality (NRM) and relapse were 19% and 25%, respectively. Of the 81 patients who died in the CsA group, disease recurrence (n=31), GvHD (n=20) and infection (n=17) were the most common causes of death. One hundred twenty seven patients died in the CsA+MMF group; cause of death was relapse for 53, GvHD for 28 and infection for 28 of them. The 2-year GVHD-free relapse-free survival (GRFS), leukemia- free survival (LFS), and overall survival (OS) were 45%, 56% and 60%, respectively. On multivariate analysis (MVA), no statistically significant differences were found among the two GvHD prophylaxis groups with respect to relapse, NRM, LFS, OS, acute and chronic GvHD. A positive cytomegalovirus serology of the donor was associated with higher NRM [HR=2.03, p<0.001] and higher cGvHD [HR=1.44, p=0.03] and a lower OS [HR 1.66, p<0.001], LFS [HR=1.69, p=0.001] and GRFS [HR=1.75, p<0.001]. In a subgroup analysis of patients in CR1 who received PBSC, (CsA alone, n=138; CsA+MMF, n=257), no differences were detected between the two groups for relapse, NRM, LFS, OS, or aGvHD, but patients who received CsA alone tended to have a higher cGvHD (41% vs 33%, p=0.05). However, on MVA, although the risk of cGvHD was lower in the CsA+MMF group, this finding was not statistically significant [HR=0.67, p=0.08]. Adverse cytogenetics was an independent risk factor for relapse [HR=2.22, p<0.001]. In this study, we observed comparable outcomes in patients with AML in CR1 who underwent MUD transplantation and RIC with CsA+MMF or CsA alone as GvHD prophylaxis. This suggests that both strategies may be considered valid approaches. Additional randomized trials are needed to further assess which patients could benefit from the addition of MMF in GvHD prophylaxis. Disclosures Blaise: Pierre Fabre medicaments: Honoraria; Molmed: Consultancy, Honoraria; Sanofi: Honoraria; Jazz Pharmaceuticals: Honoraria. Socie:Alexion: Consultancy. Chevallier:Daiichi Sankyo: Honoraria; Jazz Pharmaceuticals: Honoraria; Incyte: Consultancy, Honoraria. Mohty:Jazz Pharmaceuticals: Honoraria, Research Funding." @default.
• W2989346945 created "2019-11-22" @default.
• W2989346945 creator A5008084507 @default.
• W2989346945 creator A5014705544 @default.
• W2989346945 creator A5021867441 @default.
• W2989346945 creator A5022161221 @default.
• W2989346945 creator A5025108931 @default.
• W2989346945 creator A5025925500 @default.
• W2989346945 creator A5036207495 @default.
• W2989346945 creator A5037455697 @default.
• W2989346945 creator A5040159118 @default.
• W2989346945 creator A5040417184 @default.
• W2989346945 creator A5042277356 @default.
• W2989346945 creator A5049494863 @default.
• W2989346945 creator A5058925624 @default.
• W2989346945 creator A5063206095 @default.
• W2989346945 creator A5069084023 @default.
• W2989346945 creator A5086668079 @default.
• W2989346945 creator A5089360800 @default.
• W2989346945 date "2019-11-13" @default.
• W2989346945 modified "2023-10-17" @default.
• W2989346945 title "Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT" @default.
• W2989346945 doi "https://doi.org/10.1182/blood-2019-122251" @default.
• W2989346945 hasPublicationYear "2019" @default.
• W2989346945 type Work @default.
• W2989346945 sameAs 2989346945 @default.
• W2989346945 citedByCount "0" @default.
• W2989346945 crossrefType "journal-article" @default.
• W2989346945 hasAuthorship W2989346945A5008084507 @default.
• W2989346945 hasAuthorship W2989346945A5014705544 @default.
• W2989346945 hasAuthorship W2989346945A5021867441 @default.
• W2989346945 hasAuthorship W2989346945A5022161221 @default.
• W2989346945 hasAuthorship W2989346945A5025108931 @default.
• W2989346945 hasAuthorship W2989346945A5025925500 @default.
• W2989346945 hasAuthorship W2989346945A5036207495 @default.
• W2989346945 hasAuthorship W2989346945A5037455697 @default.
• W2989346945 hasAuthorship W2989346945A5040159118 @default.
• W2989346945 hasAuthorship W2989346945A5040417184 @default.
• W2989346945 hasAuthorship W2989346945A5042277356 @default.
• W2989346945 hasAuthorship W2989346945A5049494863 @default.
• W2989346945 hasAuthorship W2989346945A5058925624 @default.
• W2989346945 hasAuthorship W2989346945A5063206095 @default.
• W2989346945 hasAuthorship W2989346945A5069084023 @default.
• W2989346945 hasAuthorship W2989346945A5086668079 @default.
• W2989346945 hasAuthorship W2989346945A5089360800 @default.
• W2989346945 hasBestOaLocation W29893469452 @default.
• W2989346945 hasConcept C126322002 @default.
• W2989346945 hasConcept C128057223 @default.
• W2989346945 hasConcept C141071460 @default.
• W2989346945 hasConcept C2776694085 @default.
• W2989346945 hasConcept C2776755627 @default.
• W2989346945 hasConcept C2777408962 @default.
• W2989346945 hasConcept C2779263901 @default.
• W2989346945 hasConcept C2779972918 @default.
• W2989346945 hasConcept C2780611847 @default.
• W2989346945 hasConcept C2781413609 @default.
• W2989346945 hasConcept C2911091166 @default.
• W2989346945 hasConcept C71924100 @default.
• W2989346945 hasConcept C90924648 @default.
• W2989346945 hasConceptScore W2989346945C126322002 @default.
• W2989346945 hasConceptScore W2989346945C128057223 @default.
• W2989346945 hasConceptScore W2989346945C141071460 @default.
• W2989346945 hasConceptScore W2989346945C2776694085 @default.
• W2989346945 hasConceptScore W2989346945C2776755627 @default.
• W2989346945 hasConceptScore W2989346945C2777408962 @default.
• W2989346945 hasConceptScore W2989346945C2779263901 @default.
• W2989346945 hasConceptScore W2989346945C2779972918 @default.
• W2989346945 hasConceptScore W2989346945C2780611847 @default.
• W2989346945 hasConceptScore W2989346945C2781413609 @default.
• W2989346945 hasConceptScore W2989346945C2911091166 @default.
• W2989346945 hasConceptScore W2989346945C71924100 @default.
• W2989346945 hasConceptScore W2989346945C90924648 @default.
• W2989346945 hasIssue "Supplement_1" @default.
• W2989346945 hasLocation W29893469451 @default.
• W2989346945 hasLocation W29893469452 @default.
• W2989346945 hasLocation W29893469453 @default.
• W2989346945 hasOpenAccess W2989346945 @default.
• W2989346945 hasPrimaryLocation W29893469451 @default.
• W2989346945 hasRelatedWork W1955322177 @default.
• W2989346945 hasRelatedWork W2066816406 @default.
• W2989346945 hasRelatedWork W2092132051 @default.
• W2989346945 hasRelatedWork W2307932783 @default.
• W2989346945 hasRelatedWork W2360634842 @default.
• W2989346945 hasRelatedWork W2560664961 @default.
• W2989346945 hasRelatedWork W3174720739 @default.
• W2989346945 hasRelatedWork W3180209262 @default.
• W2989346945 hasRelatedWork W3198847730 @default.
• W2989346945 hasRelatedWork W4315498210 @default.
• W2989346945 hasVolume "134" @default.
• W2989346945 isParatext "false" @default.
• W2989346945 isRetracted "false" @default.
• W2989346945 magId "2989346945" @default.
• W2989346945 workType "article" @default.